Importantly, we also failed to document increased anti-tumor activity despite less than 20% residual Myc expression in TAMs or tumors of LysMCre/+;Mycfl/fl hosts in the MC38 and KPT allograft models, as well as in the endogenous Gp130F/F adenoma model. The gene discussed is MYC; the disease is adenoma.